• Home
  1. Home
  2. Haematological malignancies following temozolomide treatment for paediatric high-grade glioma
Scientific article
English

Haematological malignancies following temozolomide treatment for paediatric high-grade glioma

ContributorsKarremann, Michael; Krämer, Nadja; Hoffmann, Marion; Wiese, Maria; Beilken, Andreas; Corbacioglu, Selim; Dilloo, Dagmar; Driever, Pablo Hernáiz; Scheurlen, Wolfram; Kulozik, Andreas; Gielen, Gerrit H; Von Bueren, Andréorcid; Dürken, Matthias; Kramm, Christof M
Published inEuropean Journal of Cancer, vol. 81, p. 1-8
Publication date2017
Abstract

Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the risk of SHMs following TMZ in paediatric HGG.

Keywords
  • Adolescent
  • Antineoplastic Agents
  • Alkylating/adverse effects
  • Austria/epidemiology
  • Child
  • Child
  • Preschool
  • Dacarbazine/adverse effects/analogs & derivatives
  • Female
  • Follow-Up Studies
  • Germany/epidemiology
  • Glioma/drug therapy
  • Hematologic Neoplasms/chemically induced/epidemiology
  • Humans
  • Incidence
  • Infant
  • Kaplan-Meier Estimate
  • Male
  • Switzerland/epidemiology
Affiliation entities
Research groups
Citation (ISO format)
KARREMANN, Michael et al. Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. In: European Journal of Cancer, 2017, vol. 81, p. 1–8. doi: 10.1016/j.ejca.2017.04.023
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN0959-8049
484views
0downloads

Technical informations

Creation30/08/2018 14:50:00
First validation30/08/2018 14:50:00
Update time13/10/2025 19:02:59
Status update15/03/2023 08:34:36
Last indexation09/12/2025 13:27:46
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack